28284884|t|Risk of advanced lesions at the first follow-up colonoscopy after polypectomy of diminutive versus small adenomatous polyps of low-grade dysplasia
28284884|a|The current guidelines for surveillance after polypectomy do not distinguish between diminutive (1-5 mm) and small (6-9 mm) polyps with low-grade dysplasia (LGD). We aimed to evaluate the risk for advanced neoplasia on follow-up colonoscopy. We retrospectively analyzed 443 patients whose worst finding at index colonoscopy was polypectomy of 1 to 5 or 6 to 9 mm polyps with LGD and those who underwent a follow-up colonoscopy. During a mean follow-up of 32.0 months (interquartile range 13-48 months), advanced neoplasia was found in 26 patients (5.9%). Among all included patients (n = 443), advanced neoplasia was found in 13 of 310 patients (4.2%) of the 1- to 5-mm group versus 13 of 133 patients (9.8%) of the 6- to 9-mm group (hazard ratio [HR], 3.49; 95% confidence interval [CI], 1.6-7.6). Among the patients with 1 to 2 polyps resected (n = 313), advanced neoplasia was found in 8 of 231 patients (3.5%) of the 1- to 5-mm group versus 8 of 82 patients (9.8%) of the 6- to 9-mm group (HR 3.97; 95% CI, 1.47-10.7). Among the patients with â‰¥3 polyps resected (n = 130), advanced neoplasia was found in 5 of 79 patients (6.3%) of the 1- to 5-mm group versus 5 of 51 patients (9.8%) of the 6- to 9-mm group (HR 2.4; 95% CI, 0.7-8.36). Fair bowel preparation also was associated with the risk for advanced neoplasia at follow-up (HR 3.87, 95% CI, 1.70-8.82). Our findings suggest that among patients with up to 9-mm adenomatous polyps, a polyp size of 6 to 9 mm, >2 polyps, and fair bowel preparation are associated with advanced neoplasia.
28284884	0	4	Risk	T078	C0035647
28284884	8	16	advanced	T080	C0205179
28284884	17	24	lesions	T033	C0221198
28284884	32	37	first	T081	C0205435
28284884	38	47	follow-up	T058	C1522577
28284884	48	59	colonoscopy	T060	C0009378
28284884	60	65	after	T079	C0687676
28284884	66	77	polypectomy	T061	C0521210
28284884	81	91	diminutive	T081	C1282918
28284884	99	104	small	T081	C0700321
28284884	105	123	adenomatous polyps	T191	C0206677
28284884	127	136	low-grade	T080	C1282907
28284884	137	146	dysplasia	T046	C0334044
28284884	151	158	current	T079	C0521116
28284884	159	169	guidelines	T170	C0162791
28284884	174	186	surveillance	T058	C0733511
28284884	187	192	after	T079	C0687676
28284884	193	204	polypectomy	T061	C0521210
28284884	232	242	diminutive	T081	C1282918
28284884	256	261	small	T081	C0700321
28284884	271	277	polyps	T190	C0032584
28284884	283	292	low-grade	T080	C1282907
28284884	293	302	dysplasia	T046	C0334044
28284884	304	307	LGD	T046	C0334044
28284884	322	330	evaluate	T058	C0220825
28284884	335	339	risk	T078	C0035647
28284884	344	352	advanced	T080	C0205179
28284884	353	362	neoplasia	T191	C0027651
28284884	366	375	follow-up	T058	C1522577
28284884	376	387	colonoscopy	T060	C0009378
28284884	392	416	retrospectively analyzed	T062	C0035363
28284884	421	429	patients	T101	C0030705
28284884	436	441	worst	T080	C1522166
28284884	453	470	index colonoscopy	T058	C3274817
28284884	475	486	polypectomy	T061	C0521210
28284884	510	516	polyps	T190	C0032584
28284884	522	525	LGD	T046	C0334044
28284884	552	561	follow-up	T058	C1522577
28284884	562	573	colonoscopy	T060	C0009378
28284884	584	588	mean	T081	C0444504
28284884	589	598	follow-up	T058	C1522577
28284884	607	613	months	T079	C0439231
28284884	615	634	interquartile range	T081	C1711350
28284884	641	647	months	T079	C0439231
28284884	650	658	advanced	T080	C0205179
28284884	659	668	neoplasia	T191	C0027651
28284884	673	678	found	T033	C0150312
28284884	685	693	patients	T101	C0030705
28284884	721	729	patients	T101	C0030705
28284884	741	749	advanced	T080	C0205179
28284884	750	759	neoplasia	T191	C0027651
28284884	764	769	found	T033	C0150312
28284884	783	791	patients	T101	C0030705
28284884	817	822	group	T078	C0441833
28284884	840	848	patients	T101	C0030705
28284884	874	879	group	T078	C0441833
28284884	881	893	hazard ratio	T081	C2985465
28284884	895	897	HR	T081	C2985465
28284884	910	929	confidence interval	T081	C0009667
28284884	931	933	CI	T081	C0009667
28284884	956	964	patients	T101	C0030705
28284884	977	983	polyps	T190	C0032584
28284884	984	992	resected	T061	C0015252
28284884	1004	1012	advanced	T080	C0205179
28284884	1013	1022	neoplasia	T191	C0027651
28284884	1027	1032	found	T033	C0150312
28284884	1045	1053	patients	T101	C0030705
28284884	1079	1084	group	T078	C0441833
28284884	1100	1108	patients	T101	C0030705
28284884	1134	1139	group	T078	C0441833
28284884	1141	1143	HR	T081	C2985465
28284884	1154	1156	CI	T081	C0009667
28284884	1180	1188	patients	T101	C0030705
28284884	1197	1203	polyps	T190	C0032584
28284884	1204	1212	resected	T061	C0015252
28284884	1224	1232	advanced	T080	C0205179
28284884	1233	1242	neoplasia	T191	C0027651
28284884	1247	1252	found	T033	C0150312
28284884	1264	1272	patients	T101	C0030705
28284884	1298	1303	group	T078	C0441833
28284884	1319	1327	patients	T101	C0030705
28284884	1353	1358	group	T078	C0441833
28284884	1360	1362	HR	T081	C2985465
28284884	1372	1374	CI	T081	C0009667
28284884	1387	1391	Fair	T080	C1548785
28284884	1392	1397	bowel	T023	C0021853
28284884	1398	1409	preparation	T052	C1521827
28284884	1419	1434	associated with	T080	C0332281
28284884	1439	1443	risk	T078	C0035647
28284884	1448	1456	advanced	T080	C0205179
28284884	1457	1466	neoplasia	T191	C0027651
28284884	1470	1479	follow-up	T058	C1522577
28284884	1481	1483	HR	T081	C2985465
28284884	1494	1496	CI	T081	C0009667
28284884	1514	1522	findings	T033	C0243095
28284884	1542	1550	patients	T101	C0030705
28284884	1567	1585	adenomatous polyps	T191	C0206677
28284884	1589	1599	polyp size	T201	C1299212
28284884	1617	1623	polyps	T190	C0032584
28284884	1629	1633	fair	T080	C1548785
28284884	1634	1639	bowel	T023	C0021853
28284884	1640	1651	preparation	T052	C1521827
28284884	1656	1671	associated with	T080	C0332281
28284884	1672	1680	advanced	T080	C0205179
28284884	1681	1690	neoplasia	T191	C0027651